-
Mashup Score: 37Analysis of @FilipJankuMD FOLLOWERS - 5 month(s) ago
My followers live in USA (67%), UK.(6%)… Get your map: fedica.com/!FilipJankuMD
Source: fedica.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 26
We investigated naporafenib (LXH254), a pan-RAF kinase inhibitor, with or without spartalizumab, in patients with advanced solid tumors harboring MAPK pathway alterations.
Source: www.ejcancer.comCategories: General Medicine News, Hem/OncsTweet-
One of my prior life efforts @MDAndersonNews coming to the daylight. Pan-RAFi #naporafenib with or without PD1 showed some early signals of activity in MAPK pathway-driven cancers. Best of luck to @Erasca, which is now in charge of further development. https://t.co/NeeBQwA2kr https://t.co/UHiYhFOTdj
-
-
Mashup Score: 9
Data presented support broad potential therapeutic applications of MRT-6160 in a variety of autoimmune and inflammatory disorders driven by underlying dysregulation of T- and B-cells, including rheumatoid arthritis Investigational New Drug filing for MRT-6160 expected in 1H 2024 Data will be
Source: ir.monterosatx.comCategories: General Medicine News, Hem/OncsTweet-
Check out poster #82 from @MonteRosaTx at #ACR23 on VAV1 molecular glue degrader (#MGD) in collagen-induced arthritis autoimmune disease model #ontonewheights https://t.co/QwGPHbEryc
-
-
Mashup Score: 1
Roche is forging a new partnership with a startup focused on protein degradation. The multinational pharma company announced Tuesday it is paying $50 million upfront to team up with Monte Rosa Therapeutics and its slate of “molecular glue” programs that it argues can target proteins central to the degradation process.
Source: endpts.comCategories: Latest Headlines, Oncologists1Tweet-
RT @endpts: Roche is forging a new partnership with a startup focused on protein degradation. $GLUE https://t.co/ux16Qj6fAJ
-
-
Mashup Score: 3Targeting MYC-Driven Cancers With a Molecular Glue Degrader - 8 month(s) ago
Molecular glue degraders offer new opportunities for therapeutic development beyond current applications of immunomodulatory drugs, which can expand to nonhematological solid tumors, inflammation, autoimmunity, neurologic disorders, and genetic and metabolic diseases.
Source: dailynews.ascopubs.orgCategories: Latest Headlines, Oncologists1Tweet-
Molecular glue degraders are disrupting undruggable and difficult-to-drug target space. Get acquainted!!! #OnToNewHeights @MonteRosaTx #ASCODailyNews @ASCO https://t.co/1Ungknk9qa
-
-
Mashup Score: 0Z nuly ke stamilionovým prodejům. Dva mladí Češi poprvé popisují, jak vybudovali Niceboy - 10 month(s) ago
Sluchááátka od Niceboyeee, repráááky od Niceboyeee… co do vtíravosti může tahle reklama, která léta hraje v českých rádiích, konkurovat i Alze. Dotěrný spot ani název ovšem nijak nenapovídají, že za populární značkou elektroniky stojí dva mladí Češi. Jiří Zima a Daniel Janků, dva třicátníci z…
Source: Hospodářské noviny (HN.cz)Categories: Hem/Oncs, Latest HeadlinesTweet-
Congrats my “little brother” @DanielJanku #NiceBoy. You rock!!! https://t.co/0RDzDXq7l7
-
-
Mashup Score: 0First Opinion Podcast: 73: Do chatbots have more time to be empathetic than physicians? on Apple Podcasts - 12 month(s) ago
Show First Opinion Podcast, Ep 73: Do chatbots have more time to be empathetic than physicians? – May 17, 2023
Source: Apple PodcastsCategories: Hem/Oncs, Latest HeadlinesTweet-
Good episode of @statnews podcast #FirstOpinion with @JL_Lycette https://t.co/qvwV3w7oeX
-
-
Mashup Score: 0Researchers report first disclosures of 12 novel cancer agents - AACR Annual Meeting News - 12 month(s) ago
The AACR Chemistry in Cancer Research working group organized three special sessions at the Annual Meeting that featured first disclosures on the discovery, structure, and mechanism of action of 12 novel cancer agents that have recently entered into phase I clinical trials or will do so in the next few months.
Source: AACR Annual Meeting NewsCategories: Hem/Oncs, Latest HeadlinesTweet-
https://t.co/zidhPKQQSu
-
-
Mashup Score: 2Monte Rosa Therapeutics Appoints Dr. Jan Skvarka to Board of Directors | Monte Rosa Therapeutics - 1 year(s) ago
BOSTON, March 23, 2023 (GLOBE NEWSWIRE) — Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a clinical stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the appointment of Jan Skvarka, Ph.D., MBA to its Board of Directors. Dr.
Source: Monte Rosa TherapeuticsCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @MonteRosaTx: We are excited to have @jskvarka join our Board of Directors, read the full press release here: https://t.co/lwY7yJhRXt ht…
-
-
Mashup Score: 0Successful Treatment of Non-Langerhans Cell Histiocytosis with the MEK Inhibitor Trametinib: A Multicenter Analysis - 1 year(s) ago
Key Points. MAPK alterations are a hallmark of Erdheim-Chester and Rosai-Dorfman Disease.The MEK inhibitor trametinib is active in non-Langerhans histiocytosis,
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Targeting MAPK has become a new paradigm in #ECD and #histiocytosis. @FDAOncology approved vemurafenib and cobimetinib. @NCCN includes trametinib and dabarfenib and here is the evidence from @AshleyAaroe, @Dr_R_Kurzrock, Eli Diamond and others https://t.co/n4ARsLdwrq
-
My followers live in USA (67%), UK.(6%)... Get your map: https://t.co/PW3TDHbMJR https://t.co/ncqfzAkxHv